Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc.

INO

Classificação em ações #23454
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research,... Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
Preço da ação
$1.02
Última sincronização: 2026-10-20
Valor de mercado
$70.13M
Variação (1 dia)
1.50%
Variação (1 ano)
-87.38%
País
US
Negociar Inovio Pharmaceuticals, Inc. (INO)

Categoria

Healthcare
Número de ações em circulação para Inovio Pharmaceuticals, Inc. (INO)
Número de ações em circulação em October 2026: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Inovio Pharmaceuticals, Inc., o número atual de ações em circulação é 0. No final de October 2026, a empresa tinha 0 ações em circulação. O número de ações em circulação é geralmente afetado por desdobramentos de ações e recompra de ações.
Histórico de ações em circulação da Inovio Pharmaceuticals, Inc. (INO) de 2026 a 2026
Ações em circulação no final de cada ano
Ano Ações em circulação Alterar
Não há dados suficientes para as datas fornecidas.
Ações em circulação de empresas semelhantes ou concorrentes
Empresa Ações em circulação Diferença País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL